COVID-19 Vaccines and Vaccination Report: The Nigeria Perspective
Journal of Advances in Microbiology,
COVID-19 vaccine like other vaccines is developed to produce acquired immunity against the virus which causes coronavirus disease. The spread of the virus led to quick study by various science laboratories all over the world on the preventive role and the mortality rate reduction potential of covid vaccines. Celebration has been witnessed in different part of the world for the role the vaccines played against various cases arising from coronavirus infection. This review focused on the adverse event of coronavirus vaccines with perspective to the Nigerian populace. The type of vaccines approved for use by the WHO include; viral vector vaccines which has the Oxford-Astrazenca in its class, RNA vaccines, whole virus vaccines (having the Sinopharm, and Sinovac in it class), and protein subunit vaccines (with Novavax COVID-19 vaccines and (ESI, 2021), EpiVacCorona in it class). In Nigeria, about 8,439 mild adverse reactions have been reported by the National Health Care Development Agency (NPHCDA), following the administration of the first doses of the Oxford-AstraZeneca COVID-19 vaccine. The report showed that out of over a million persons who received the vaccine, 8,439 persons showed mild adverse effects, while 52 persons suffered moderate to severe adverse events on receiving the jab. Generally, the vaccine has proven to be effective in combating and limiting infection and spread of covid-19 among the citizenry.
- protein sub-unit
How to Cite
Subbarao K. The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 2021;29(7).
Vergano D. COVID-19 Vaccines Work Way Better Than We Had Ever Expected. Scientists Are Still Figuring Out Why. BuzzFeed News; 2021.
Module 2 – Subunit vaccines". WHO Vaccine Safety Basics; 2021.
Understanding Viral Vector COVID-19 Vaccines. U.S. Centers for Disease Control and Prevention (CDC). 13 April 2021; 2021
Rachel M. The four types of COVID-19 vaccine – a snapshot. HealthcareI Tnews; 2021.
O'Reilly P. A Phase III study to investigate a vaccine against COVID-19. ISRCTN; 2020.
Corum J, Carl Z. How Gamaleya's Vaccine Works. The New York Times; 2021.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants. US National Library of Medicine. Archived from the original on 26 September 2020. Retrieved July 26, 2021.
Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586 (7830): 516–27.
Park KS, Sun X, Aikins ME, Moon JJ. Non-viral COVID-19 vaccine delivery systems. Advanced Drug Delivery Reviews. 2021;169:137–51.
Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Molecular Therapy. 2019;27(4): 710–28.
Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019;28:100766.
Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends". Immunology and Cell Biology. 2004;82(5):488–96.
Linda G. How effective are COVID-19 vaccines in the real-world? Gavi; 2021.
Abstract View: 147 times
PDF Download: 66 times